Akebia Therapeutics (AKBA) has been given a "Strong Buy" consensus rating by analysts, indicating positive sentiment towards the stock1. This rating is based on the average price target of $7.5, which is significantly higher than the current trading price of $1.9912.
Despite the positive rating, it's important to note that the stock's performance has been mixed. While the company has had a strong run with a 105% annual gain, its revenue has been declining, which has contributed to a low price-to-sales ratio compared to the industry3. Additionally, the company has recently missed earnings expectations, which could impact investor confidence2. Overall, while the consensus rating is positive, investors should consider these mixed signals and conduct their own analysis before making investment decisions.
11/12/2024 02:01pm
Aime finds your next big stock
